Patents by Inventor Eckard Wimmer

Eckard Wimmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12054749
    Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: August 6, 2024
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, The Research Foundation for the State University of New York
    Inventors: Peter L. Collins, Cyril Le Nouen, Linda G. Brock, Ursula J. Buchholz, Joshua Marc Dinapoli, Steffen Mueller, Eckard Wimmer
  • Publication number: 20240228981
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Application
    Filed: November 17, 2023
    Publication date: July 11, 2024
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Publication number: 20240228978
    Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.
    Type: Application
    Filed: April 1, 2024
    Publication date: July 11, 2024
    Applicant: The Research Foundation for the State of University New York
    Inventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steve Skiena, Chen Yang
  • Patent number: 11549101
    Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: January 10, 2023
    Assignee: The Research Foundation for State University of New York
    Inventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steven Skiena, Chen Yang
  • Publication number: 20220325252
    Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.
    Type: Application
    Filed: June 2, 2022
    Publication date: October 13, 2022
    Inventors: Peter L. COLLINS, Cyril LE NOUEN, Linda G. BROCK, Ursula J. BUCHHOLZ, Joshua Marc DINAPOLI, Steffen MUELLER, Eckard WIMMER
  • Publication number: 20220298492
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Application
    Filed: October 28, 2021
    Publication date: September 22, 2022
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Patent number: 11371024
    Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 28, 2022
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Peter L. Collins, Cyril Le Nouën, Linda G. Brock, Ursula J. Buchholz, Joshua Marc DiNapoli, Steffen Mueller, Eckard Wimmer
  • Patent number: 11162080
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: November 2, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Publication number: 20210009962
    Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.
    Type: Application
    Filed: June 10, 2019
    Publication date: January 14, 2021
    Inventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steven Skiena, Chen Yang
  • Patent number: 10400220
    Abstract: This invention provides an attenuated virus comprising a modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein encoding sequence relative to a first host while the codon pair bias relative to a second host is not substantially reduced. In another embodiment, the invention provides an attenuated virus comprising modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein-encoding sequence relative to a first host and a second host. The attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the attenuated virus.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 3, 2019
    Assignee: The Research Foundation for The State University of New York
    Inventors: Eckard Wimmer, Steffen Mueller, Bruce Futcher, Sam Shen, Charles Stauft, Charles Ward
  • Patent number: 10316294
    Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: June 11, 2019
    Assignee: The Research Foundation for The State University of New York
    Inventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steven Skiena, Chen Yang
  • Publication number: 20190169235
    Abstract: This invention provides a modified protein encoding sequence containing nucleotide substitutions at multiple locations in the protein encoding sequence, wherein the substitutions introduce rare hexamers. These hexamers may be Frame Dependent, or depleted in only the reading frame, or Frame Independent, or depleted in all three frames. Modified protein encoding se quences of the present invention may include modified viruses useful for vaccines.
    Type: Application
    Filed: November 7, 2016
    Publication date: June 6, 2019
    Inventors: Bruce Futcher, Justin Gardin, Steven Skiena, Alisa Yurovsky, Eckard Wimmer, Steffen Mueller
  • Publication number: 20190010469
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Application
    Filed: July 16, 2018
    Publication date: January 10, 2019
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Publication number: 20190002837
    Abstract: This invention provides an attenuated virus comprising a modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein encoding sequence relative to a first host while the codon pair bias relative to a second host is not substantially reduced. In another embodiment, the invention provides an attenuated virus comprising modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein-encoding sequence relative to a first host and a second host. The attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the attenuated virus.
    Type: Application
    Filed: September 8, 2015
    Publication date: January 3, 2019
    Applicant: The Research Foundation for The State University of New York
    Inventors: Eckard Wimmer, Steffen Mueller, Bruce Futcher, Sam Shen, Charles Stauft, Charles Ward
  • Publication number: 20180208906
    Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.
    Type: Application
    Filed: March 16, 2018
    Publication date: July 26, 2018
    Inventors: Peter L. Collins, Cyril Le Nouën, Linda G. Brock, Ursula J. Buchholz, Joshua Marc DiNapoli, Steffen Mueller, Eckard Wimmer
  • Patent number: 10023845
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: July 17, 2018
    Assignee: The Research Foundation for The State University of New York
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Patent number: 9957486
    Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 1, 2018
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Research Foundation For the State University of New York
    Inventors: Peter L. Collins, Cyril Le Nouën, Linda G. Brock, Ursula J. Buchholz, Joshua Marc DiNapoli, Steffen Mueller, Eckard Wimmer
  • Publication number: 20170067030
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Application
    Filed: September 7, 2016
    Publication date: March 9, 2017
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Patent number: 9476032
    Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: October 25, 2016
    Assignee: The Research Foundation for The State University of New York
    Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
  • Publication number: 20160024477
    Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.
    Type: Application
    Filed: March 15, 2014
    Publication date: January 28, 2016
    Inventors: Steffen MUELLER, Eckard WIMMER, Bruce FUTCHER, Steven SKIENA, Chen YANG